ELTP offers a cash-rich, low-multiple specialty generic platform with pipeline upside, but Vyvanse price erosion and distributor concentration make it a speculative asymmetric bet.
Elite Pharmaceuticals Inc. (ELTP) operates as a specialty generic pharmaceutical company focused on the development, manufacture, and commercial distribution of niche oral solid dose drug products [cite: 1, 2]. The company operates a fully compliant Current Good Manufacturing Practice (cGMP) and Drug Enforcement Administration (DEA) registered research, development, and manufacturing facility in Northvale, New Jersey [cite: 2]. This facility serves as the foundation for the company's specialization in high-barrier, federally regulated Schedule II controlled substances, including central nervous system (CNS) stimulants and opioid pain management products [cite: 2, 3].
Historically, the corporate business model relied heavily on licensing and indirect distribution agreements, where third-party marketing organizations managed sales and split gross profits [cite: 4, 5]. Over the past three fiscal years, the business has undergone a transition toward direct nationwide distribution under its proprietary "Elite Laboratories, Inc." label [cite: 1, 6]. Direct sales grew to represent approximately 44% of consolidated revenues in the fiscal year ended March 31, 2026, with indirect sales through marketing partners making up the remaining 56% [cite: 6]. This transition represents a structural shift toward a more profitable, self-directed commercial model, nationwide [cite: 1, 6].
Elite's revenue generation is entirely concentrated within the United States generic pharmaceutical market [cite: 1]. The commercial portfolio is categorized into three key product areas:
* CNS Stimulants: Immediate-release and extended-release amphetamine formulations (generic equivalents of Adderall and Adderall XR), alongside generic Vyvanse (Lisdexamfetamine Dimesylate), which collectively serve as the primary drivers of corporate revenue [cite: 7, 8].
* Pain Management: Opioid and non-opioid therapeutics, including generic Percocet (Oxycodone Hydrochloride and Acetaminophen), generic Revia (Naltrexone Hydrochloride), and the recently commercialized generic Dolophine (Methadone Hydrochloride) [cite: 1, 8].
* Bariatrics: Phentermine Hydrochloride tablets and capsules targeting weight management [cite: 8, 9].
The company distributes its products nationwide through a highly concentrated customer base, with three major pharmaceutical wholesale distributors accounting for 81% of total revenues [cite: 10]. Wholesale customers, buying groups, and retail pharmacy chains choose Elite over larger, diversified competitors because of its consistent compliance track record, reliable supply chain, and established capability to secure necessary DEA active ingredient manufacturing quotas [cite: 2, 3].
Elite’s commercial portfolio is anchored by high-demand niche generics, particularly in the ADHD and pain management markets [cite: 1, 8]. To provide investors with complete clarity regarding what is actually manufactured and commercialized, the active commercial portfolio is detailed below:
| Product Name | Branded Equivalent | Therapeutic Category | Regulatory Class | Commercial Status and Market Context |
|---|---|---|---|---|
| Amphetamine IR Tablets | Adderall® | CNS Stimulant / ADHD | Schedule II | Captures ~20% of the $400 million US generic market [cite: 7]. |
| Amphetamine ER Capsules | Adderall XR® | CNS Stimulant / ADHD | Schedule II | Captures ~16% of the $800 million US generic market [cite: 7]. |
| Lisdexamfetamine Capsules | Vyvanse® | CNS Stimulant / ADHD | Schedule II | Launched late FY2025; achieved full-year contribution in FY2026 [cite: 1, 9]. |
| Oxycodone APAP Tablets | Percocet® | Pain Management | Schedule II | Launched in FY2026 under the direct Elite label [cite: 1, 9]. |
| Methadone HCl Tablets | Dolophine® | Pain Management | Schedule II | Launched in April 2026 targeting a $22 million retail market [cite: 1, 11]. |
| Ropinirole ER Tablets | Requip XL® | Parkinson's Disease | Non-Controlled | Launched in August 2026 targeting a $10 million therapy class [cite: 1, 11]. |
| Naltrexone HCl Tablets | Revia® | Pain / Addiction | Non-Controlled | Launched under the Elite label, boosting direct revenue [cite: 1, 9]. |
| Phentermine HCl Tablets/Capsules | Adipex-P® | Bariatric | Schedule IV | Long-standing cash generator sold directly under the Elite label [cite: 8, 9]. |
Beyond the currently marketed formulations, the company filed an Abbreviated New Drug Application (ANDA) in June 2026 for an undisclosed generic anticoagulant targeting a massive $26 billion branded retail class [cite: 12]. While this application represents significant pipeline optionality, generic entry is contingent on resolving unexpired patents and exclusivities [cite: 12]. In addition, Elite announced positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic in June 2026, which is being compiled for an upcoming ANDA filing [cite: 1, 13].
In the highly deflationary generic pharmaceutical industry, traditional economic moats are rare [cite: 3]. Elite does not possess a broad moat, but it has developed a narrow, defensible competitive advantage structured around three barriers:
* Regulatory Barriers and Quota Allocations: The manufacturing of Schedule II controlled substances is heavily restricted by the DEA and FDA [cite: 2, 3]. Beyond requiring cGMP and DEA-registered facilities, competitors must secure annual active pharmaceutical ingredient (API) manufacturing quotas from the DEA to produce controlled drugs [cite: 2, 3]. The DEA limits the aggregate production of these substances to control national supply [cite: 3]. Elite's historical regulatory compliance allows it to secure consistent API allocations, creating a significant regulatory barrier to entry against non-quota-aligned competitors [cite: 2, 3].
* Direct-to-Wholesaler Cost Advantage: By moving away from legacy licensing models, Elite has eliminated the royalty splits previously paid to third-party marketing firms [cite: 4, 6]. This shift expands consolidated gross margins to 50.4%, giving the company a cost advantage that allows it to maintain profitability during competitive price wars [cite: 4, 14].
* Asset Density: Operating a single, highly integrated, non-unionized facility in Northvale, New Jersey, keeps administrative and manufacturing overhead low compared to diversified generic conglomerates [cite: 2].
The aggregate addressable market for Elite's marketed ADHD products is estimated at $1.2 billion in annual generic retail sales [cite: 7]. This is divided between the $400 million generic Adderall immediate-release (IR) market and the $800 million extended-release (ER) market [cite: 7]. The secondary addressable markets include the $22 million retail market for generic Methadone Hydrochloride tablets [cite: 11], and the bariatric classes addressed by Phentermine [cite: 8, 9].
The largest potential expansion opportunity remains the generic anticoagulant ANDA submitted in June 2026, which addresses a $26 billion branded retail class [cite: 12]. If the company successfully overcomes patent litigations, even a minor market share capture (e.g., 0.5% to 1.0%) would significantly alter Elite's long-term financial trajectory [cite: 12].
Elite operates in a highly competitive generic pharmaceutical industry against large, vertically integrated multinationals, including Teva Pharmaceutical, Amneal Pharmaceuticals, and Viatris [cite: 15, 16]. In its core stimulant niche, Elite is holding its ground, maintaining a steady 20% volume share of the Adderall IR market and a 16% volume share of the Adderall ER market [cite: 7].
However, in newly opened generic classes, Elite is vulnerable to rapid competitive entry [cite: 17]. In the generic Vyvanse (Lisdexamfetamine) market, the entry of multiple generic manufacturers in late 2025 and early 2026 triggered a severe "competitive market adjustment" across the industry [cite: 17, 18]. This adjustment significantly compressed market pricing and forced Elite to take price cuts and accept lower gross margins to defend its volume share, illustrating that market share in the generic industry is often defended at the expense of profitability [cite: 17, 18].
Elite announced its most recent quarterly financial results for the first quarter of fiscal year 2027 (ended June 30, 2026) on August 13, 2026 [cite: 17].
The company reported consolidated revenues of $32.4 million, representing a 19.5% decline (or $7.9 million) compared to the record-setting $40.3 million achieved in the prior year's first quarter [cite: 17, 18]. This contraction was primarily driven by lower average selling prices and compressed gross margins on the Lisdexamfetamine (generic Vyvanse) product line, following severe industry-wide competitive price adjustments [cite: 17, 18].
Income from operations fell 65% year-over-year to $7.5 million, down from $21.7 million in the prior-year period [cite: 17, 18]. This operational contraction highlights the sensitivity of Elite’s business model to generic price erosion, as fixed manufacturing overhead costs were distributed over a lower revenue base [cite: 9, 19]. Despite the severe decline in operating profit, Elite remained profitable, reporting net income attributable to common shareholders of $5.9 million [cite: 17]. This performance was sequentially stable, aligning with the operational results of the prior three quarters, which indicates that the hyper-normal profits captured during the initial Vyvanse generic launch have fully normalized [cite: 17].
| Financial Metric | Q1 FY2027 (Ended 6/30/2026) | Q1 FY2026 (Ended 6/30/2025) | Year-over-Year Change (%) | Sequential Context (Prior 3-Quarter Run-Rate) |
|---|---|---|---|---|
| Consolidated Revenue | $32.4M [cite: 17] | $40.3M [cite: 17] | -19.5% [cite: 17] | Inline with sequential quarters [cite: 17] |
| Income from Operations | $7.5M [cite: 17] | $21.7M [cite: 17] | -65.4% [cite: 17] | Inline with sequential quarters [cite: 17] |
| Operating Margin | 23.1% | 53.8% | -30.7 pp | Margin compression fully normalized [cite: 17] |
| Net Income to Common | $5.9M [cite: 17] | $16.1M [cite: 17] | -63.4% | Reflects normalized direct sales run-rate [cite: 17] |
Because Elite is a microcap stock traded on the OTCQB venture market, it lacks formal sell-side analyst consensus revenue or earnings per share (EPS) estimates [cite: 20]. Therefore, standard "beat/miss" metrics relative to Wall Street consensus are not applicable. Management did not provide or modify quantitative forward guidance during the release, in line with its historical policy of not issuing formal earnings forecasts [cite: 6, 21].
During the corresponding investor conference call on August 14, 2026, management highlighted that despite the margin pressure in the Vyvanse franchise, the company’s capital structure remains exceptionally clean, characterized by $29.8 million in cash, record-high working capital of $95 million, and minimal long-term debt of $4.7 million [cite: 6]. The launch of generic Requip XL in August 2026 and the submission of the anticoagulant ANDA were framed as key operational catalysts to offset the Vyvanse pricing pressure [cite: 11, 12]. The stock market reacted neutrally to the Q1 FY2027 release, with the stock price maintaining its horizontal trading range of $0.36 to $0.37, as the market had already priced in the expected normalization of generic Vyvanse margins following a 7.57% drop during the prior annual results release in late June 2026 [cite: 1, 22].
Prior to the Q1 FY2027 normalization, Elite experienced a multi-year phase of rapid revenue expansion, driven by its direct label transition and key product launches [cite: 4, 6].
| Fiscal Year | Consolidated Revenue ($M) | YoY Revenue Growth (%) | Consolidated Gross Profit ($M) | Gross Profit Margin (%) | Operating Income ($M) | Operating Profit Margin (%) |
|---|---|---|---|---|---|---|
| FY 2022 | 32.3 [cite: 19] | +27.1% [cite: 19] | 14.8 [cite: 19] | 45.8% | 5.1 [cite: 19] | 15.8% |
| FY 2023 | 34.2 [cite: 19] | +5.9% [cite: 19] | 16.6 [cite: 19] | 48.5% | 3.7 [cite: 19] | 10.8% |
| FY 2024 | 56.6 [cite: 19] | +65.8% [cite: 19] | 26.4 [cite: 19] | 46.6% | 10.8 [cite: 19] | 19.1% |
| FY 2025 | 84.0 [cite: 19] | +48.4% [cite: 19] | 40.1 [cite: 19] | 47.7% | 19.6 [cite: 19] | 23.3% |
| FY 2026 | 148.9 [cite: 1, 9] | +77.1% [cite: 9, 19] | 75.0 [cite: 19] | 50.4% [cite: 14] | 49.1 [cite: 1, 9] | 33.0% [cite: 20] |
Over the five-year period ending March 31, 2026, Elite achieved an annualized revenue compound annual growth rate (CAGR) of 46.5% [cite: 19]. Operating income grew at an even faster rate, reflecting substantial fixed-cost absorption at the Northvale manufacturing facility [cite: 2, 19].
Elite’s current valuation multiples must be analyzed in the context of its generic business model and structural balance sheet cash.
Using the fully-year consolidated audited FY2026 figures (ended March 31, 2026) as the trailing twelve-month (TTM) base, the stock trades at the following multiples:
The low trailing valuation multiples (such as a 10.95x P/E) reflect the stock market’s skepticism regarding the sustainability of Elite's FY2026 earnings [cite: 3, 26]. The market is pricing Elite as a highly volatile commodity generic drug manufacturer, anticipating that price erosion in the stimulant franchise will offset the benefits of new product launches [cite: 3, 17]. To justify a higher multiple, Elite must demonstrate that its direct commercial label can stabilize operating margins at or above 25% through consistent, sequential product rollouts, such as Methadone and Requip XL, thereby reducing its operational dependence on the highly competitive amphetamine and Vyvanse drug classes [cite: 1, 6, 17].
Elite is exposed to significant pricing and approval execution risks. In the generic drug industry, product approvals are highly commoditized. While Elite has successfully transitioned to direct commercial labeling, it remains highly vulnerable to the "generic cliff" [cite: 3, 4]. When competitive entry occurs, average selling prices can decline by 80% or more within a single fiscal year [cite: 3]. The operational performance of generic Vyvanse in Q1 FY2027 is a prime example of this risk, where a single pricing adjustment by competitors led to a 65% drop in operating income [cite: 17, 18]. Additionally, pipeline execution risks are prominent; the proposed anticoagulant generic targets a massive $26 billion market, but faces intense patent litigation from the brand sponsor, which could delay FDA approval or launch for several years [cite: 12].
Elite's commercial model features extreme distribution risk. The company relies on major pharmaceutical distributors to place its products in retail networks, resulting in three major wholesale customers controlling 81% of total revenues [cite: 10].
+-----------------------------------------------------------+
| Elite Pharmaceuticals Revenue |
+------------------------------------+----------------------+
| Top 3 Wholesalers: 81% | All Others: 19% |
+------------------------------------+----------------------+
This structural concentration grants extreme pricing power to distributors, who can demand unfavorable chargeback adjustments or threaten to delist Elite's products in favor of larger generic competitors [cite: 6, 10]. Furthermore, because Elite manufactures Schedule II controlled substances, its production volumes are constrained by annual DEA raw material quotas [cite: 2, 3]. If the DEA reduces Elite’s amphetamine or opioid API allocation due to shifting federal drug enforcement policies, Elite's production volumes would decline regardless of commercial demand [cite: 3].
While Elite’s balance sheet is currently strong with minimal debt, its historical capital structure presents legacy dilution challenges [cite: 6, 25]. The company has a large share count of 1.077 billion shares outstanding, driven by historical equity issuances to fund operations [cite: 6, 23]. Additionally, Elite has a significant volume of warrants outstanding that are approaching their 10-year expiration dates [cite: 6]. The revaluation of these warrants under GAAP creates massive non-cash derivative expenses or gains on the statement of operations, creating substantial volatility in GAAP net income [cite: 4, 6]. While management has discussed non-dilutive cashless exercise options with the majority warrant holders, any cash-based exercise would increase the outstanding share count and dilute EPS [cite: 6].
Generic manufacturers are highly sensitive to global supply chain disruptions and inflation in active raw ingredients. Wafers, chemicals, and specialized APIs are often sourced from single-source international suppliers [cite: 27]. Elite operates out of a single facility in New Jersey, creating a structural operational bottleneck [cite: 2]. Any local utility disruption, labor dispute, or regulatory issue at the Northvale plant would immediately halt all manufacturing operations [cite: 2]. Externally, proposed generic drug tariffs and potential supply chain compliance mandates (such as the Drug Supply Chain Security Act - DSCSA) present ongoing compliance costs that could squeeze margins for smaller generic operators [cite: 3, 24].
This five-year scenario model projects Elite’s equity valuation to the fiscal year ending March 31, 2031 (Year 5). The projections are driven by the normalization of the core stimulant business, the commercialization of pipeline products, and changes in the capital structure. The analysis assumes a baseline share count of 1.077 billion shares, a current share price of $0.36 USD, and a clean net cash position [cite: 22, 23].
This scenario assumes that the core amphetamine and Vyvanse franchises stabilize at normalized, lower margins following the price adjustments of 2026 [cite: 17, 18]. New launches (Methadone and Requip XL) grow steadily but do not achieve dominant market share [cite: 1, 11]. The pipeline anticoagulant is delayed by patent litigation and does not launch within the 5-year window [cite: 12].
* 5-Year Sales CAGR: 10.0% (Revenues grow from $148.9M in FY2026 to $239.8M in FY2031) [cite: 9].
* Operating Margin: Establishes at 22.0% (reflecting permanent generic price erosion) [cite: 17].
* Net Margin: 16.5% (assuming a fully normalized 25% tax rate as NOLs are exhausted) [cite: 6].
* Year 5 Net Income: $39.6 million USD.
* Share Count: Expands to 1.15 billion (due to modest warrant and option exercises) [cite: 6].
* Year 5 EPS: $0.034 USD.
* Exit P/E Multiple: 11.0x (in line with historical microcap generic averages) [cite: 26].
* Projected Share Price: $0.37 USD.
* 5-Year Total Return: 2.8% (annualized return of 0.5%).
This scenario assumes that Elite successfully navigates patent hurdles to launch its generic anticoagulant by Year 3, capturing 1.5% of the $26 billion market [cite: 12]. The core stimulant franchise stabilizes due to ongoing brand shortages, and the company secures up-listed Nasdaq trading, expanding its institutional investor base [cite: 3, 6].
* 5-Year Sales CAGR: 25.0% (Revenues reach $454.4M in FY2031) [cite: 9].
* Operating Margin: Expands to 30.0% due to operating leverage and high-margin direct pipeline sales [cite: 6].
* Net Margin: 22.5% (reflecting higher direct label mix and operational efficiency) [cite: 6].
* Year 5 Net Income: $102.2 million USD.
* Share Count: Held to 1.10 billion (due to cashless warrant exercises and share buybacks financed by positive cash flow) [cite: 6].
* Year 5 EPS: $0.093 USD.
* Exit P/E Multiple: 15.0x (reflecting Nasdaq listing and a more diversified, higher-margin portfolio) [cite: 6].
* Projected Share Price: $1.40 USD.
* 5-Year Total Return: 288.9% (annualized return of 31.2%).
This scenario assumes severe pricing pressure across all generic product lines, combined with a reduction in DEA API quotas [cite: 3, 17]. Distributor consolidation further compresses margins, and Elite fails to obtain timely regulatory approvals for its pipeline molecules [cite: 10, 12].
* 5-Year Sales CAGR: -5.0% (Revenues decline to $115.2M in FY2031) [cite: 9].
* Operating Margin: Contracts to 12.0% as fixed overhead pressures the lower revenue base [cite: 2].
* Net Margin: 9.0% (reflecting pricing compression and higher compliance costs) [cite: 28].
* Year 5 Net Income: $10.4 million USD.
* Share Count: Dilutes to 1.20 billion shares [cite: 23].
* Year 5 EPS: $0.009 USD.
* Exit P/E Multiple: 8.0x (reflecting a declining, low-margin business model) [cite: 3].
* Projected Share Price: $0.07 USD.
* 5-Year Total Return: -80.6% (annualized return of -28.1%).
The future equity value is calculated using the following bridge:
$\text{Projected Share Price} = \frac{\text{Year 5 Projected Revenue} \times \text{Projected Net Profit Margin}}{\text{Projected Share Count}} \times \text{Projected Exit P/E Multiple}$
The trajectory of the projected share prices across the scenarios is presented in the table below:
| Fiscal Year | High Case Share Price (USD) | Base Case Share Price (USD) | Low Case Share Price (USD) |
|---|---|---|---|
| Current (FY2026) | 0.36 [cite: 22] | 0.36 [cite: 22] | 0.36 [cite: 22] |
| Year 1 (FY2027) | 0.45 | 0.36 | 0.28 |
| Year 2 (FY2028) | 0.58 | 0.36 | 0.21 |
| Year 3 (FY2029) | 0.78 | 0.37 | 0.15 |
| Year 4 (FY2030) | 1.05 | 0.37 | 0.10 |
| Year 5 (FY2031) | 1.40 | 0.37 | 0.07 |
The probability-weighted target price is computed by multiplying each scenario's projected share price by its subjective probability weight:
$\text{Target Price} = (1.40 \times 0.20) + (0.37 \times 0.55) + (0.07 \times 0.25) = 0.280 + 0.204 + 0.018 = \$0.50 \text{ USD}$
At a probability-weighted target of $0.50 USD, Elite is currently undervalued relative to its risk-adjusted potential, offering an implied 38.9% upside over 5 years.
| Scenario | Revenue / key scale metric in Year 5 ($M) | Margin / earnings assumption | Valuation multiple assumption | Current share price ($) | Implied future share price ($) | 5-year total return (%) | Annualized return (%) | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | 454.4 [cite: 9] | 22.5% Net Margin [cite: 6] | 15.0x P/E [cite: 6] | 0.36 [cite: 22] | 1.40 | +288.9% | +31.2% | 20.0% |
| Base Case | 239.8 [cite: 9] | 16.5% Net Margin [cite: 6] | 11.0x P/E [cite: 26] | 0.36 [cite: 22] | 0.37 | +2.8% | +0.5% | 55.0% |
| Low Case | 115.2 [cite: 9] | 9.0% Net Margin [cite: 28] | 8.0x P/E [cite: 3] | 0.36 [cite: 22] | 0.07 | -80.6% | -28.1% | 25.0% |
| Weighted | 251.6 | 16.6% Net Margin | 11.1x P/E | 0.36 | 0.50 | +38.9% | +6.8% | 100.0% |
ASYMMETRIC SPECULATIVE POTENTIAL
This scorecard provides a qualitative assessment of Elite’s business model and governance. It is designed solely to analyze structural risks and strengths, and does not constitute financial advice or investment recommendations.
This qualitative evaluation indicates that while Elite has built a strong balance sheet and a viable, self-funding niche generic model, its high customer concentration and exposure to generic price erosion present ongoing execution risks that warrant a conservative valuation.
HIGHLY SPECULATIVE UNDERDOG
Elite Pharmaceuticals represents a compelling, self-funded turnaround story in the specialty microcap generic space, although it remains exposed to structural industry risks. This analysis is presented strictly for educational purposes and does not constitute a recommendation to purchase or sell securities.
The primary catalyst for the positive investment thesis is the successful transition to the direct "Elite Laboratories" label [cite: 1, 6]. This transition has significantly expanded corporate gross margins and allowed the company to accumulate $29.8 million in cash and nearly $100 million in working capital [cite: 6, 25]. This solid financial profile provides a buffer against industry downturns and eliminates the dilution risks typical of microcap biotech stocks [cite: 6, 19]. Additionally, the pipeline is highly asymmetric; any regulatory success or launch of the pending anticoagulant or anticonvulsant ANDAs could significantly expand Elite's revenue base [cite: 12, 13]. Furthermore, management's plans to cashless-resolve expiring warrants and explore an up-listing to a major national exchange (such as Nasdaq) could serve as significant catalysts to unlock institutional capital [cite: 6].
However, these positive catalysts are balanced by significant risks. The company operates in a commoditized, deflationary industry where generic pricing can erode rapidly upon competitor entry [cite: 3, 17]. The Q1 FY2027 financial performance clearly demonstrated this dynamic, as generic Vyvanse margin compression offset growth in other lines, leading to a 65% drop in operating income [cite: 17, 18]. Additionally, the company faces extreme customer concentration, relying on three major distributors for 81% of its revenues, which exposes it to significant distribution and counterparty risks [cite: 10]. Ultimately, Elite is not a stable compounding asset. Instead, it is a low-multiple, asset-rich microcap with a solid balance sheet that is currently undervalued relative to its historical performance and pipeline optionality [cite: 14, 26]. At its current valuation, the stock offers an asymmetric speculative opportunity for investors willing to accept generic price erosion and customer concentration risks in exchange for significant potential upside if pipeline approvals materialize [cite: 10, 12, 17].
BALANCED RISK-REWARD SPECULATION
Elite is currently trading in a range of $0.36 to $0.37 USD, consolidating below its declining 200-day moving average [cite: 20, 22]. The stock is trading approximately 13.12% below its 200-day moving average, reflecting a broader 1-year underperformance of -32.1% due to market concerns over generic Vyvanse margin compression [cite: 14, 20].
Price ($)
0.40 | ------- (200-Day Moving Average)
0.38 | /
0.36 | === === === (Current Price Consolidation Zone)
0.34 |_______________________
Time (August 2026)
In the short term, technical indicators suggest range-bound consolidation between support at $0.33 and resistance at $0.40 [cite: 24, 26]. The immediate stock outlook is neutral, and a breakout is unlikely until subsequent quarterly results demonstrate that new product launches (such as Methadone and Requip XL) are successfully stabilizing corporate operating income [cite: 1, 17].
BEARISH-LEANING HORIZONTAL CONSOLIDATION
View Elite Pharmaceuticals, Inc. (ELTP) stock page
Loading the interactive version of this report…